Skip to main content
SpringerLink
Log in

Pharmacology of Neurotoxins: Onabotulinum Toxin (Botox®), Abobotulinum Toxin (Dysport®), Incobotulinum Toxin (Xeomin®), and Prabotulinumtoxin-xvfs (Jeuveau™)

  • Chapter
  • First Online:
Aesthetic Procedures: Nurse Practitioner's Guide to Cosmetic Dermatology

  • 1298 Accesses

Abstract

Neurotoxins, or botulinum neurotoxins type A (BoNT/A), are commonly known as Botox®, Dysport®, and Xeomin® for cosmetic use and are the most commonly performed non-surgical aesthetic procedure in the world. A new FDA approved BoNT/A called Jeuveau™ (prabotulinumtoxin-xvfs) was released to the US market mid-June 2019. BoNT/A treatment in the facial muscles causes relaxation of the muscle fibers by cleaving SNAP-25 and subsequently reducing the formation of SNARE complexes and acetylcholine release from the peripheral nerve cells into the neuromuscular junction. This results in relaxation of the targeted muscle or muscle group and leads to smoother overlying skin because the muscle is no longer able to fully contract and cause a line. The smoothing result of the neurotoxin is temporary and lasts approximately 3–4 months, although the medication package inserts state up to 6 months. This chapter will review the pharmacology of the most commonly used neurotoxins for cosmetic use.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Allergan. Botox® cosmetic prescribing information [package insert]. Irvine: Allergan; 2017.

    Google Scholar 

  • American Society of Plastic Surgeons (ASPS). 2017 top five cosmetic plastic surgery procedures. 2017. https://www.plasticsurgery.org/documents/News/Statistics/2017/cosmetic-procedure-trends-2017.pdf. Available from: https://www.plasticsurgery.org/.

  • Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol. 2001;8(Suppl 5):21–9.

    Article  Google Scholar 

  • OnabotulinumtoxinA (Botox): drug information Lexicomp [internet]. 2018. Available from: https://www.uptodate.com/contents/onabotulinumtoxina-botox-drug-information?search=botulinum%20toxin%20type%20a&source=search_result&selectedTitle=1~124&usage_type=default&display_rank=1#F6038541.

  • Brooks V. The history of neuroscience in autobiography. Cambridge: Academic; 2001. 115 p.

    Google Scholar 

  • Burgen A, Dickens F, Zatman L. The action of botulinum toxin on the neuro-muscular junction. J Physiol. 1949;109(1–2):10–24.

    Article  CAS  Google Scholar 

  • Carli L, Montecucco C, Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve. 2009;40(3):374–80.

    Article  CAS  Google Scholar 

  • Carruthers A, Carruthers J. In: Dover JS, editor. Procedures in cosmetic dermatology: botulinum toxin. Philadelphia: Elsevier Saunders; 2005a. 141 p.

    Google Scholar 

  • Carruthers A, Carruthers J. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg. 2005b;31(10):1297–303.

    Article  CAS  Google Scholar 

  • Evolus. Juveau (r) highlights of prescribing information [package insert]. Evolus 2019. Available from: https://info.evolus.com/hubfs/Jeuveau_USPI.pdf.

  • Fonfria E, Maignel J, Lezmi S, Martin V, Splevins A, Shubber S, et al. The expanding therapeutic utility of botulinum neurotoxins. Toxins (Basel). 2018;10(5):208.

    Article  Google Scholar 

  • Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D. 2015;15(1):1–9.

    Article  CAS  Google Scholar 

  • International Society of Aesthetic Plastic Surgeons (ISAPS). ISAPS international study on aesthetic/cosmetic procedures performed in 2016: world wide. New York: ISAPS; 2016. Available from: https://www.isaps.org/wpcontent/uploads/2017/10/GlobalStatistics2016-1.pdf.

  • Ipsen Biopharmaceuticals Inc. Dysport® full prescribing information. Basking Ridge: IB Inc; 2017.

    Google Scholar 

  • Kassir R, Kolluru A, Kassir M. Triple-blind, prospective, internally controlled comparative study between abobotulinumtoxinA and onabotulinumtoxinA for the treatment of facial Rhytids. Dermatol Ther (Heidelb). 2013;3(2):179–89.

    Article  Google Scholar 

  • Magid M, Keeling BH, Reichenberg JS. Neurotoxins: expanding uses of neuromodulators in medicine--major depressive disorder. Plast Reconstr Surg. 2015;136(5 Suppl):111S–9S.

    Article  CAS  Google Scholar 

  • Merz Pharmaceuticals LLC. Xeomin® full prescribing information. Greensboro: MP LLC; 2018.

    Google Scholar 

  • Mohindru A, Bulloch S, Kronfeld N, et al. Analysis of clinical and non-clinical, peer reviewed, published studies investigating the use of commercially available botulinum toxins: an online literature review. Poster presented at: second international congress on treatment of dystonia (ICTD), Hannover, Germany; 2013.

    Google Scholar 

  • Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm (Vienna). 2013;120(2):275–90.

    Article  CAS  Google Scholar 

  • Pellett S, Tepp WH, Whitemarsh R, Bradshaw M, Johnson EA, Johnson BA. In vivo onset and duration of action varies for Botulinum neurotoxin A subtypes 1–5. Toxicon. 2015;107:37–42.

    Article  CAS  Google Scholar 

  • Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69(2):200–35.

    Article  CAS  Google Scholar 

  • Rizo J, Sudhof TC. The membrane fusion enigma: SNAREs, Sec1/Munc18 proteins, and their accomplices--guilty as charged? Annu Rev Cell Dev Biol. 2012;28:279–308.

    Article  CAS  Google Scholar 

  • Rzany B, Bechara FG, Feise K, Heckmann M, Rapprich S, Worle B. Update of the S1 guidelines on the definition and treatment of primary hyperhidrosis. J Dtsch Dermatol Ges. 2018;16(7):945–52.

    PubMed  Google Scholar 

  • Simpson L. The life history of a botulinum toxin molecule. Toxicon. 2013;68:40–59.

    Article  CAS  Google Scholar 

  • Sundaram H, et al. Global aesthetics consensus: botulinum toxin type A—evidence-based review, emerging concepts, and consensus recommendations for aesthetic use, including updates on complications. Plast Reconstr Surg. 2016;137(3):518–29.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Former Clinical Assistant Professor, University of California, Irvine, CA, USA

    Beth Haney

Authors
  1. Beth Haney
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Haney, B. (2020). Pharmacology of Neurotoxins: Onabotulinum Toxin (Botox®), Abobotulinum Toxin (Dysport®), Incobotulinum Toxin (Xeomin®), and Prabotulinumtoxin-xvfs (Jeuveau™). In: Aesthetic Procedures: Nurse Practitioner's Guide to Cosmetic Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-030-19948-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-19948-7_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-19947-0

  • Online ISBN: 978-3-030-19948-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation